Timber Hill’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
Sell
-15,200
Closed -$1.76M 1102
2017
Q1
$1.76M Sell
15,200
-12,700
-46% -$1.48M 0.01% 767
2016
Q4
$3.35M Buy
27,900
+25,900
+1,295% +$2.87M 0.02% 664
2016
Q3
$225K Sell
2,000
-12,500
-86% -$1.44M ﹤0.01% 1830
2016
Q2
$1.8M Buy
14,500
+9,000
+164% +$1.09M 0.01% 956
2016
Q1
$618K Buy
5,500
+2,200
+67% +$229K ﹤0.01% 1477
2015
Q4
$359K Sell
3,300
-300
-8% -$34.3K ﹤0.01% 1852
2015
Q3
$359K Sell
3,600
-10,600
-75% -$1.15M ﹤0.01% 1964
2015
Q2
$1.62M Buy
14,200
+5,800
+69% +$703K 0.01% 1199
2015
Q1
$878K Buy
+8,400
New +$895K ﹤0.01% 1491
2013
Q4
Sell
-5,500
Closed -$931K 2989
2013
Q3
$931K Sell
5,500
-9,600
-64% -$1.49M ﹤0.01% 1999
2013
Q2
$2.29M Buy
+15,100
New +$2.14M 0.01% 1314

Other funds holding CLB

Timber Hill's CLB Position: Q2 2017 in Review

Timber Hill sold out of Core Laboratories (CLB) in Q2 2017, closing a stake of 6,655 shares — an estimated $769K sold.

Timber Hill first reported a position in CLB in Q2 2015 and held it in 5 quarters. The position peaked at $1.15M in Q2 2016. 360 funds tracked by Wall St. Rank hold CLB as of Q2 2017.

  • Timber Hill reported no remaining Core Laboratories position as of Q2 2017 after selling out during the quarter.
  • Timber Hill sold 6,655 Core Laboratories shares in Q2 2017, an estimated $769K.
  • Timber Hill first reported a position in Core Laboratories in Q2 2015 and held it in 5 quarters.
  • Timber Hill's Core Laboratories position peaked at $1.15M in Q2 2016.
  • 360 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2017.

Based on Timber Hill's 13F filing for Q2 2017, filed 9 Aug 2017.